DHA and EPA Down-regulate COX-2 Expression through Suppression of $NF-{\kappa}B$ Activity in LPS-treated Human Umbilical Vein Endothelial Cells

  • Lee, Soon-Ae (Department of Obstetrics & Gynecology, Gyeongsang National University) ;
  • Kim, Hye-Jung (Institute of Health Sciences, Gyeongsang National University) ;
  • Chang, Ki-Churl (Institute of Health Sciences, Gyeongsang National University) ;
  • Baek, Jong-Chul (Department of Obstetrics & Gynecology, Gyeongsang National University) ;
  • Park, Ji-Kwon (Department of Obstetrics & Gynecology, Gyeongsang National University) ;
  • Shin, Jeong-Kyu (Department of Obstetrics & Gynecology, Gyeongsang National University) ;
  • Choi, Won-Jun (Department of Obstetrics & Gynecology, Gyeongsang National University) ;
  • Lee, Jong-Hak (Department of Obstetrics & Gynecology, Gyeongsang National University) ;
  • Paik, Won-Young (Department of Obstetrics & Gynecology, Gyeongsang National University)
  • Published : 2009.08.31

Abstract

Inflammatory processes of vascular endothelial cells play a key role in the development ofatherosclerosis. We determined the anti-inflammatory effects and mechanisms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on LPS-treated human umbilical vein endothelial cells (HUVECs) to evaluate their cardioproteerive potential. Cells were pretreated with DHA, EPA, or troglitazone prior to activation with LPS. Expression of COX-2, prostaglandin $E_2$ ($PGE_2$) and IL-6 production, and $NF-{\kappa}B$ activity were measured by Western blot, ELISA, and luciferase activity, respectively. Results showed that EPA, DHA, or troglitazone significantly reduced COX-2 expression, $NF-{\kappa}B$ luciferase activity, and $PGE_2$ and IL-6 production in a dose-dependent fashion. Interestingly, low doses (10 ${\mu}$M) of DHA and EPA, but not troglitozone, significantly increased the activity of $NF-{\kappa}B$ in resting HUVECs. Our study suggests that while DHA, EPA, and troglitazone may be protective on HUVECs under inflammatory conditions in a dose-dependent manner. However there may be some negative effects when the concentrations are abnormally low, even in normal endothelium.

Keywords

References

  1. Abeywardena MY, Head RJ. Long chain n-3 polyunsaturatedfatty acids and blood vessel function. Cardiovasc Res 52: 361−371, 2001 https://doi.org/10.1016/S0008-6363(01)00406-0
  2. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 100: 1751−1756, 2003 https://doi.org/10.1073/pnas.0334211100
  3. Blaschke F, Spanheimer R, Khan M, Law RE. Vascular effects of TZDs: New implications. Vascul Pharmacol 45: 3−18, 2006 https://doi.org/10.1016/j.vph.2005.11.009
  4. Cipollone F, Fazia ML. Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk. Curr Atheroscler Rep 8: 245−251, 2006 https://doi.org/10.1007/s11883-006-0080-2
  5. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169: 453−459, 2001 https://doi.org/10.1677/joe.0.1690453
  6. Engler MB, Engler MM, Browne A, Sun YP, Sievers R. Mechanisms of vasorelaxation induced by eicosapentaenoic acid (20:5n-3) in WKY rat aorta. Br J Pharmacol 131: 1793−1799, 2000 https://doi.org/10.1038/sj.bjp.0703754
  7. Goua M, Mulgrew S, Frank J, Rees D, Sneddon AA, Wahle KW. Regulation of adhesion molecule expression in human endothelial and smooth muscle cells by omega-3 fatty acids and conjugated linoleic acids: involvement of the transcription factor NF-kappaB? Prostaglandins Leukot Essent Fatty Acids 78: 33−43, 2008 https://doi.org/10.1016/j.plefa.2007.10.004
  8. Hayden MS, Ghosh S. Signaling to NF-$\kappa$B. Genes Dev 18: 2195−2224, 2004 https://doi.org/10.1101/gad.1228704
  9. Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 25: 1220−1224, 2005 https://doi.org/10.1161/01.ATV.0000159163.52632.1b
  10. Kim HJ, Tsoy I, Park JM, Chung JI, Shin SC, Chang KC. Anthocyanins from soybean seed coat inhibit the expression of TNF-alpha-induced genes associated with ischemia/reperfusion in endothelial cell by NF-kappaB-dependent pathway and reduce rat myocardial damages incurred by ischemia and reperfusion in vivo. FEBS Lett 580: 1391−1397, 2006 https://doi.org/10.1016/j.febslet.2006.01.062
  11. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106: 2747−2757, 2002 https://doi.org/10.1161/01.CIR.0000038493.65177.94
  12. Libby CP. Inflammation in atherosclerosis. Nature 420: 868−874, 2002 https://doi.org/10.1038/nature01323
  13. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T, Weksler BB, De Caterina R. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP (H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci U S A 103: 15184−15189, 2006 https://doi.org/10.1073/pnas.0510086103
  14. Massaro M, Scoditti E, Carluccio MA, De Caterina R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids 79: 109−115, 2008 https://doi.org/10.1016/j.plefa.2008.09.009
  15. Philip CC. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83 Suppl: 1505S−1519S, 2006
  16. Rosen ED, Spiegelman BM. PPAR$\gamma$: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731−37734, 2001
  17. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115−126, 1999 https://doi.org/10.1056/NEJM199901143400207
  18. Scher JU, Pillinger MH. The anti-inflammatory effects of prostaglandins. J Investig Med 2009 Feb 20. [Epub ahead of print] https://doi.org/10.231/JIM.0b013e31819aaa76
  19. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197−1204, 2000 https://doi.org/10.1084/jem.192.8.1197
  20. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196: 1025−1037, 2002 https://doi.org/10.1084/jem.20020760
  21. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American heart association. Circulation 89: 2462−2478, 1994 https://doi.org/10.1161/01.CIR.89.5.2462
  22. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 24: 2227−2236, 2004 https://doi.org/10.1161/01.ATV.0000147534.69062.dc
  23. Triantafilou M, Gamper FG, Lepper PM, Mouratis MA, Schumann C, Harokopakis E, Schifferle RE, Hajishengallis G, Triantafilou K. Lipopolysaccharides from atherosclerosis-associated bacteria antagonize TLR4, induce formation of TLR2/1/CD36 complexes in lipid rafts and trigger TLR2-induced inflammatory responses in human vascular endothelial cells. Cell Microbiol 9: 2030−2039, 2007 https://doi.org/10.1111/j.1462-5822.2007.00935.x
  24. Umetani M, Mataki C, Minegishi N, Yamamoto M, Hamakubo T, Kodama T. Function of GATA transcription factors in induction of endothelial vascular cell adhesion molecule-1 by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 21: 917−922, 2001 https://doi.org/10.1161/01.ATV.21.6.917
  25. Vikatmaa P, Lajunen T, Ikonen TS, Pussinen PJ, Lepäntalo M, Leinonen M, Saikku P. Chlamydial lipopolysaccharide (cLPS) is present in atherosclerotic and aneurysmal arterial wall-cLPS levels depend on disease manifestation. Cardiovasc Pathol 2009 Jan 14. [Epub ahead of print] https://doi.org/10.1016/j.carpath.2008.10.012